Bioprinting: Prospects, considerations and challenges for application in South African clinical environments

Bioprinting advances have revolutionised drug discovery and are set to disrupt biomedical research and medical application through the development of reproducible, fine-tuned functional 3D tissues and, eventually, whole organs. This intersectional bottom-up approach of additive manufacturing requires collaboration between tissue engineers, materials chemists, software and electrical engineers and medical practitioners for the software, hardware and wetware required by this disruptive technology. This review provides a current overview of the state of the art of bioprinting and the biomaterials/bioinks required, as well as the challenges and prospects for medical application in South Africa

Transplantation of gene-modified haematopoietic stem cells: Application and clinical considerations

Autologous and allogeneic haematopoietic stem cell (HSC) transplantation has been performed in patients with various malignant and non-malignant haematological disorders for more than 50 years. Ex vivo gene modification of HSCs for autologous transplantation opens up new therapeutic avenues for genetic and infectious diseases. Major advances have been made over the last three decades with respect to gene modification of HSCs and transplantation strategies, ultimately culminating in the approval of two such therapies in Europe (Strimvelis for a rare primary immune deficiency, and LentiGlobin for beta-thalassaemia). Newer gene-modifying technologies and treatment regimens have also recently come to the fore, which hold great promise for the development of safer and more effective treatments. We provide an overview of the current state of gene-modified HSC therapies, highlighting success stories, limitations and important considerations for achieving successful translation of these therapies to the clinic